A61K31/7024

CARBON NANOTUBE COMPOSITE VECTOR HAVING SYNERGISTIC EFFECT OF PHOTOTHERMAL THERAPY AND GENE THERAPY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A carbon nanotube composite vector having a synergistic effect of photothermal therapy and gene therapy, a preparation method therefor, and an application thereof. The vector includes a vector moiety and a gene, and the vector moiety includes carbon nanotubes, a peptide lipid, and/or an additive. A modifier is immobilized on the carbon nanotubes by a self-assembly process to prepare the composite vector that can carry and transfer the gene. The composite vector overcomes the problems that pure carbon nanotubes have poor water solubility, low biocompatibility, and poor gene carrying and transfer efficiency; moreover, the composite vector has higher photothermal conversion performances and gene transfer efficiency, reduces cytotoxicity of carbon nanotubes, and alleviates the problem of localized accumulation of carbon nanotubes. The synergistic effect of photothermal therapy and gene therapy is applied to resolve the problem in tumor treatment that the efficacy of a single treatment method is poor.

CARBON NANOTUBE COMPOSITE VECTOR HAVING SYNERGISTIC EFFECT OF PHOTOTHERMAL THERAPY AND GENE THERAPY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A carbon nanotube composite vector having a synergistic effect of photothermal therapy and gene therapy, a preparation method therefor, and an application thereof. The vector includes a vector moiety and a gene, and the vector moiety includes carbon nanotubes, a peptide lipid, and/or an additive. A modifier is immobilized on the carbon nanotubes by a self-assembly process to prepare the composite vector that can carry and transfer the gene. The composite vector overcomes the problems that pure carbon nanotubes have poor water solubility, low biocompatibility, and poor gene carrying and transfer efficiency; moreover, the composite vector has higher photothermal conversion performances and gene transfer efficiency, reduces cytotoxicity of carbon nanotubes, and alleviates the problem of localized accumulation of carbon nanotubes. The synergistic effect of photothermal therapy and gene therapy is applied to resolve the problem in tumor treatment that the efficacy of a single treatment method is poor.

CARBON NANOTUBE COMPOSITE VECTOR HAVING SYNERGISTIC EFFECT OF PHOTOTHERMAL THERAPY AND GENE THERAPY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A carbon nanotube composite vector having a synergistic effect of photothermal therapy and gene therapy, a preparation method therefor, and an application thereof. The vector includes a vector moiety and a gene, and the vector moiety includes carbon nanotubes, a peptide lipid, and/or an additive. A modifier is immobilized on the carbon nanotubes by a self-assembly process to prepare the composite vector that can carry and transfer the gene. The composite vector overcomes the problems that pure carbon nanotubes have poor water solubility, low biocompatibility, and poor gene carrying and transfer efficiency; moreover, the composite vector has higher photothermal conversion performances and gene transfer efficiency, reduces cytotoxicity of carbon nanotubes, and alleviates the problem of localized accumulation of carbon nanotubes. The synergistic effect of photothermal therapy and gene therapy is applied to resolve the problem in tumor treatment that the efficacy of a single treatment method is poor.

COMPOSITION FOR PREVENTING GRAY HAIR, PROMOTING BLACK HAIR AND PREVENTING, IMPROVING OR TREATING VITILIGO OR HYPOCHROMATISM COMPRISING FRUCTOSE 1,6-BISPHOSPHATE OR SALT, SOLVATE, STEREOISOMER OR HYDRATE THEREOF AS ACTIVE INGREDIENT

The present disclosure relates to a composition for preventing gray hair, promoting black hair and preventing, improving or treating vitiligo or hypochromatism, which contains fructose 1,6-bisphosphate or a salt, a solvate, a stereoisomer or a hydrate thereof as an active ingredient, and has been contrived to solve the problem of the prior art that appreciable effect cannot be achieved due to insignificant effect on melanin production. The composition of the present disclosure, which contains fructose 1,6-bisphosphate or a salt, a solvate, a stereoisomer or a hydrate thereof, provides superior effect of preventing gray hair, promoting black hair and treating vitiligo or hypochromatism.

Compositions containing tannic acids and uses thereof

Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are D-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

Compositions containing tannic acids and uses thereof

Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are D-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.

USE OF NOCARDIA RUBRA CELL WALL SKELETON IN TREATMENT OF THERMAL INJURY
20220193148 · 2022-06-23 ·

Provided is the use of a Nocardia rubra cell wall skeleton in the preparation of a drug for treating thermal injury.

USE OF NOCARDIA RUBRA CELL WALL SKELETON IN TREATMENT OF THERMAL INJURY
20220193148 · 2022-06-23 ·

Provided is the use of a Nocardia rubra cell wall skeleton in the preparation of a drug for treating thermal injury.

TARGETING BIOLOGICAL AGENTS TO MUCOSAL DEFECTS OF THE GASTROINTESTINAL TRACT
20220175885 · 2022-06-09 ·

Compositions are provided that target biological therapeutic agents to mucosal defects in the gastrointestinal tract by means of antacid mucosal protective agents that bind selectively to such defects.

TARGETING BIOLOGICAL AGENTS TO MUCOSAL DEFECTS OF THE GASTROINTESTINAL TRACT
20220175885 · 2022-06-09 ·

Compositions are provided that target biological therapeutic agents to mucosal defects in the gastrointestinal tract by means of antacid mucosal protective agents that bind selectively to such defects.